Ananda Pharama PLC (ANA) ORD GBP0.002
- Add to watchlist
- Create an alert
- This stock can be held in a
Business summary
Ananda Pharma plc, formerly Ananda Developments plc, is a United Kingdom-based pharmaceutical company. The Company is focused on the research and development of cannabidiol (CBD)-based therapies. It is engaged in developing medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with chemotherapy induced peripheral neuropathy (CIPN) & endometriosis) and Heart Failure with preserved Ejection Fraction (HFpEF). ACTiON is a Phase II, double blind placebo-controlled crossover randomized clinical trial (RCT) to assess its MRX1 drug candidate versus placebo in the treatment of CIPN. ENDOCAN-1 shall help determining whether a cannabinoid can reduce endometriosis-associated pain. HFpEF is a study designed to evaluate the cardioprotective effects of its MRX1 drug candidate in a preclinical HFpEF model. Its two novel cannabinoid medicines: MRX2 (CBD) and MRX2T, helps in a range of seizure types and epilepsies in children and adults.
Contact details
Important dates
General stock information
- EPIC:
- ANA
- ISIN:
- GB00BDQPXQ60
- Market cap:
- £18.70 million
- Shares in issue:
- 2.88 billion
- Sector:
- Pharmaceuticals
- Exchange:
- -
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.